Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q3 FY24 results · Oct–Dec 2023
Neuland Laboratories reported revenue from operations of ₹392.83 crore (up 45.9% from Q3 FY23) and net profit of ₹81.39 crore (up 166.4% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 392.83 | 269.25 | +45.9% | 417.75 | −6.0% |
| Other income | 2.10 | 0.93 | +125.1% | 3.05 | −31.1% |
| Total income | 394.93 | 270.18 | +46.2% | 420.80 | −6.1% |
| Profit before tax | 104.48 | 38.94 | +168.3% | 121.59 | −14.1% |
| Net profit for the period | 81.39 | 30.55 | +166.4% | 89.25 | −8.8% |
| EPS, basic (₹) | 63.44 | 23.81 | +166.4% | 69.56 | −8.8% |
| Net margin (%) | 20.7 | 11.3 | 21.4 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 392.83 | 269.25 | +45.9% | 417.75 | −6.0% |
| Other income | 2.10 | 0.93 | +125.1% | 3.05 | −31.1% |
| Total income | 394.93 | 270.18 | +46.2% | 420.80 | −6.1% |
| Profit before tax | 103.78 | 38.80 | +167.5% | 121.40 | −14.5% |
| Net profit for the period | 80.70 | 30.44 | +165.1% | 89.06 | −9.4% |
| EPS, basic (₹) | 62.90 | 23.72 | +165.2% | 69.42 | −9.4% |
| Net margin (%) | 20.5 | 11.3 | 21.3 |
Consolidated
- Filed with BSE
- 09 Feb 2024, 13:55 IST
- Board meeting
- 08 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2024, 13:55 IST
- Board meeting
- 08 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE